Shyam Poludasu, MD
Interventional Cardiology · Stillwater, OKNPI 1811171705
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (32.1%), travel and lodging and other — rather than concentrated in one kind of arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 20.5%.
Across 543 payments — averaging $67.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$8K
- Medtronic$5K
- Amgen$5K
- Abbott$3K
- Penumbra, Inc.$3K
- Acist Medical Systems, Inc.$2K
- plus $11K from 45 others
What the payments were for
- Speaking & faculty fees$7,00019%
- Travel & lodging$10,66829%
- Food & beverage$11,82732%
- Education$200%
- Other$7,38320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$7,574
- Repatha$4,908
- Indigo System$2,511
- ADVISA DR MRI SURESCAN$2,492
- Devices$2,000
- OPTIS$1,351
- VersaCross Access Solution$1,059
- Diamondback Peripheral$877
- Abre$821
- Micra$745
- ACCULINK$456
- SAPIEN 3 Ultra RESILIA$398
- FFRct$389
- HD-IVUS$309
- Impella$271
- Veltassa$200
- FLOWTRIEVER CATHETER, S$158
- CT THROMBECTOMY SYSTEM KIT$158
- AZURE XT DR MRI SURESCAN$149
- COREVALVE EVOLUT R$128
How this compares
$36,899 in reported general payments places this provider in the 85th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,261 | $1,022,367 |
| EntrestoSacubitril/Valsartan | 274 | $215,768 |
| XareltoRivaroxaban | 150 | $125,772 |
| FarxigaDapagliflozin Propanediol | 176 | $122,076 |
| MultaqDronedarone Hcl | 51 | $45,694 |
| JardianceEmpagliflozin | 24 | $33,573 |
| VascepaIcosapent Ethyl | 71 | $33,262 |
| Ranolazine ErRanolazine | 340 | $22,344 |
| Atorvastatin Calcium | 1,607 | $19,680 |
| Repatha SureclickEvolocumab | 34 | $18,384 |
| Ezetimibe | 680 | $17,631 |
| Praluent PenAlirocumab | 31 | $15,429 |
| Metoprolol Succinate | 890 | $14,101 |
| Potassium Chloride | 760 | $12,617 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 707 | $10,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $463 | $1,022,3671,261 claims |
| NovartisEntresto | $1,261 | $215,768274 claims |
| AstraZenecaFarxiga, Brilinta | $378 | $132,149190 claims |
| Johnson & JohnsonXarelto | $520 | $125,772150 claims |
| Sanofi-aventis U.S. LLCMultaq | $65 | $45,69451 claims |
| Boehringer IngelheimJardiance | $170 | $33,57324 claims |
| AmgenCorlanor | $5,236 | $3,61321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Stillwater
- Kamran MuhammadTulsa$1.4M
- George ChrysantOklahoma City$524K
- Suresh ChandrasekaranMidwest City$302K
- Jeffrey SparlingOklahoma City$231K
- Stanley ZimmermanTulsa$93K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Marcus SmithOklahoma City$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.